BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections
Sex Transm Infect
.
2022 May;98(3):235-236.
doi: 10.1136/sextrans-2022-055425.
Authors
Manik Kohli
1
2
,
Nicholas Medland
3
4
,
Helen Fifer
5
,
John Saunders
6
5
Affiliations
1
Institute for Global Health, University College London, London, UK m.kohli@ucl.ac.uk.
2
Department of Sexual Health and HIV, Central and North West London NHS Foundation Trust, London, UK.
3
The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
4
Melbourne Sexual Health Centre, Monash University Central Clinical School, Melbourne, Victoria, Australia.
5
Blood Safety, Hepatitis, STIs and HIV Division, UK Health Security Agency, London, UK.
6
Institute for Global Health, University College London, London, UK.
PMID:
35414633
PMCID:
PMC9016249
DOI:
10.1136/sextrans-2022-055425
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Doxycycline* / therapeutic use
Homosexuality, Male
Humans
Male
Sexually Transmitted Diseases* / drug therapy
Sexually Transmitted Diseases* / prevention & control
Substances
Doxycycline
Grants and funding
ACF-2020-18-014/DH_/Department of Health/United Kingdom